These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 24330516)
21. Direct cost and predictive factors for treatment in patients with ocular hypertension or early, moderate and advanced primary open-angle glaucoma: the CoGIS study in Germany. Lorenz K; Wolfram C; Breitscheidel L; Shlaen M; Verboven Y; Pfeiffer N Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):2019-28. PubMed ID: 23624617 [TBL] [Abstract][Full Text] [Related]
22. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Kymes SM; Kass MA; Anderson DR; Miller JP; Gordon MO; Am J Ophthalmol; 2006 Jun; 141(6):997-1008. PubMed ID: 16765666 [TBL] [Abstract][Full Text] [Related]
23. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model. Pradelli L; Iannazzo S; Zaniolo O Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036 [TBL] [Abstract][Full Text] [Related]
24. [When and how we start the treatment in patients with ocular hypertension or in glaucoma suspects?]. Stefan C; Ene L; Coravu CO Oftalmologia; 2014; 58(1):15-7. PubMed ID: 25145118 [TBL] [Abstract][Full Text] [Related]
25. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation. Krummenauer F; Günther KP; Witzlebf WC Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552 [TBL] [Abstract][Full Text] [Related]
26. Optimal follow-up strategies after aorto-iliac prosthetic reconstruction: a decision analysis and cost-effectiveness analysis. Post PN; Kievit J; van Bockel JH Eur J Vasc Endovasc Surg; 2004 Sep; 28(3):287-95. PubMed ID: 15288633 [TBL] [Abstract][Full Text] [Related]
27. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States. Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands. Soeteman DI; Verheul R; Meerman AM; Ziegler U; Rossum BV; Delimon J; Rijnierse P; Thunnissen M; Busschbach JJ; Kim JJ J Clin Psychiatry; 2011 Jan; 72(1):51-9. PubMed ID: 21034679 [TBL] [Abstract][Full Text] [Related]
29. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis. Konnopka A; Conrad K; Baerwald C; König HH Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570 [TBL] [Abstract][Full Text] [Related]
32. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Liew D; Park HJ; Ko SK Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890 [TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model. Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of renin-guided treatment of hypertension. Smith SM; Campbell JD Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147 [TBL] [Abstract][Full Text] [Related]
35. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for glaucoma. van Gestel A; Severens JL; Webers CA; Beckers HJ; Jansonius NM; Schouten JS Value Health; 2010; 13(4):358-67. PubMed ID: 20659272 [TBL] [Abstract][Full Text] [Related]
36. The Cost-Effectiveness Analysis of Teleglaucoma Screening Device. Thomas S; Hodge W; Malvankar-Mehta M PLoS One; 2015; 10(9):e0137913. PubMed ID: 26382956 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of noninvasive central blood pressure monitoring in the diagnosis of hypertension. Cheng HM; Pearson A; Sung SH; Yu WC; Chen CH; Karnon J Am J Hypertens; 2015 May; 28(5):604-14. PubMed ID: 25430695 [TBL] [Abstract][Full Text] [Related]
38. Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis. Sejean K; Calmus S; Durand-Zaleski I; Bonnichon P; Thomopoulos P; Cormier C; Legmann P; Richard B; Bertagna XY; Vidal-Trecan GM Eur J Endocrinol; 2005 Dec; 153(6):915-27. PubMed ID: 16322399 [TBL] [Abstract][Full Text] [Related]
39. Health economic evaluation of plasma oxysterol screening in the diagnosis of Niemann-Pick Type C disease among intellectually disabled using discrete event simulation. van Karnebeek CD; Mohammadi T; Tsao N; Sinclair G; Sirrs S; Stockler S; Marra C Mol Genet Metab; 2015 Feb; 114(2):226-32. PubMed ID: 25095726 [TBL] [Abstract][Full Text] [Related]